Cargando…

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

INTRODUCTION: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior inadequate response or intolerance to ≥ 1 non-biologic or bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R., Winthrop, Kevin, Blanco, Ricardo, Nash, Peter, Goupille, Philippe, Azevedo, Valderilio F., Salvarani, Carlo, Rubbert-Roth, Andrea, Lesser, Elizabeth, Lippe, Ralph, Lertratanakul, Apinya, Mccaskill, Reva M., Liu, John, Ruderman, Eric M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717827/ https://www.ncbi.nlm.nih.gov/pubmed/34970731 http://dx.doi.org/10.1007/s40744-021-00410-z

Ejemplares similares

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
por: Mease, Philip, et al.
Publicado: (2022)

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
por: Mease, Philip J., et al.
Publicado: (2021)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
por: McInnes, Iain B., et al.
Publicado: (2022)

Risk factors and predictors of psoriatic arthritis in patients with psoriasis
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2013)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
por: Burmester, Gerd R., et al.
Publicado: (2020)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
por: Valor-Méndez, Larissa, et al.
Publicado: (2022)

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
por: Conaghan, Philip G., et al.
Publicado: (2021)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study
por: Luchetti Gentiloni, Michele Maria, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
por: Kivitz, Alan J., et al.
Publicado: (2021)

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report
por: Serrato, Varlei A., et al.
Publicado: (2010)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Publicado: (2021)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey
por: Richette, Pascal, et al.
Publicado: (2022)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Upadacitinib: Pneumocystis jirovecii pneumonia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rvkirno9i5b2l7d8vo5jrhkn13